Does the systemic immune inflammation index (SII) predict all-cause mortality in patients with NSTEMI?
The systemic immune inflammation index is significantly elevated in patients with NSTEMI compared to those with normal coronary arteries, suggesting potential utility as a simple biomarker for risk stratification.
Objective Acute coronary syndrome (ACS) is a disease associated with high mortality and morbidity. It is essential to identify high-risk patients during hospitalization and to implement early revascularization strategies if necessary. There is a clear need for a simple, effective and cost-effective index for rapid identification of these patients in clinical practice. The aim of this study was to investigate the clinical significance of the systemic immune inflammation index (SII) in non-ST-segment elevation myocardial infarction (NSTEMI), a subgroup of ACS, and to evaluate its association with mortality. Material and Method Patients who underwent coronary angiography at the Coronary Angiography Unit of Aydın Adnan Menderes University Faculty of Medicine Research and Training Hospital between January and December 2022 were retrospectively reviewed. Individuals with a diagnosis of NSTEMI were included as group I, and individuals with normal coronary arteries during coronary angiography were included as group II (control group). Clinical variables and calculated SII values of the groups were recorded. The role of SII in predicting all-cause mortality and its effect on expected survival were evaluated. Results The median value of the SII index was significantly higher in the NSTEMI group (group I) than in the control group (group II) (p
Çayırlı et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: